Biotechnology
Industry
|
Healthcare
Sector
|
Dr. Arnon Rosenthal Ph.D.
CEO
|
NASDAQ (NGS)
Exchange
|
US0144421072
ISIN
|
US
Country
|
244
Employees
|
-
Last Dividend
|
-
Last Split
|
7 Feb 2019
IPO Date
|
Alector, Inc. is a pioneering clinical-stage biopharmaceutical company, dedicated to breaking new ground in the treatment of neurodegeneration diseases. Since its establishment in 2013, Alector has focused on developing innovative therapies that target key aspects of neurodegenerative disorders. The company is engaged in rigorous research and development efforts, leveraging its expertise in biotechnology to create solutions that could potentially transform the treatment landscape for conditions such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, among others. Headquartered in South San Francisco, California, Alector is propelled by strategic collaborations with entities like Adimab, LLC, for antibody research and development, and GlaxoSmithKline plc, focusing on the development and commercialization of specific monoclonal antibodies targeting neurodegenerative diseases.